alizapride Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
sulpiride derivatives 120 59338-93-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alizapride
  • alizapride hydrochloride
  • alizapride HCl
a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. Its effect is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS), this action prevents nausea and vomiting triggered by most stimuli.
  • Molecular weight: 315.38
  • Formula: C16H21N5O2
  • CLOGP: 2.53
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 83.14
  • ALOGS: -2.84
  • ROTB: 6

Drug dosage:

DoseUnitRoute
0.15 g O
0.15 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 28.42 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 84 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.60 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1981 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Encephalopathy 81.62 33.93 34 1614 33555 46650859
Febrile bone marrow aplasia 68.63 33.93 20 1628 6842 46677572
Hypofibrinogenaemia 51.49 33.93 11 1637 1059 46683355
Psychiatric decompensation 50.96 33.93 11 1637 1112 46683302
Persecutory delusion 41.97 33.93 11 1637 2544 46681870
Blood phosphorus decreased 41.86 33.93 12 1636 3868 46680546
Polyneuropathy 35.86 33.93 14 1634 11630 46672784

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Leukopenia 37.83 31.04 28 1566 56131 29894753
Alopecia 37.59 31.04 19 1575 19256 29931628
General physical health deterioration 36.54 31.04 35 1559 99909 29850975
Dry mouth 34.54 31.04 19 1575 22831 29928053
Thrombocytopenia 34 31.04 39 1555 137005 29813879
Mucosal inflammation 31.96 31.04 20 1574 30474 29920410

Pharmacologic Action:

SourceCodeDescription
ATC A03FA05 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
PROPULSIVES
Propulsives
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Postoperative nausea and vomiting indication 1488000
Nausea and vomiting indication 16932000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.11 acidic
pKa2 13.45 acidic
pKa3 8.72 Basic
pKa4 0.34 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2C adrenergic receptor GPCR Ki 7 WOMBAT-PK
D(2) dopamine receptor GPCR Ki 7.15 WOMBAT-PK
D(2) dopamine receptor GPCR IC50 6.70 CHEMBL

External reference:

IDSource
P55703ZRZY UNII
D07102 KEGG_DRUG
59338-87-3 SECONDARY_CAS_RN
C0051162 UMLSCUI
CHEBI:94316 CHEBI
CHEMBL290194 ChEMBL_ID
DB01425 DRUGBANK_ID
135497066 PUBCHEM_CID
4823 INN_ID
C033968 MESH_SUPPLEMENTAL_RECORD_UI
11141 IUPHAR_LIGAND_ID
17311 RXNORM
005228 NDDF
005246 NDDF
724156007 SNOMEDCT_US
734457001 SNOMEDCT_US

Pharmaceutical products:

None